Milestone Pharmaceuticals announces $125M strategic financing

Milestone Pharmaceuticals announced that it has entered into a $125M strategic funding agreement with existing shareholder, RTW Investments, LP and certain of its affiliates. Proceeds from this tailored financing, together with $64.6M of cash, cash equivalents and short-term investments as of December 31, 2022, are expected to fund Milestone’s operations into the middle of 2025, including the potential approval and launch of etripamil. Etripamil is the company’s investigational calcium channel blocker envisioned to empower patients with paroxysmal supraventricular tachycardia to treat their attacks outside of the emergency department.